Terry Podoll

1.1k citations

21 papers · 904 indexed · h-index 10

Impact in

Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Hepatotoxicity and Protection
- Antibiotics Pharmacokinetics and Efficacy
Transplantation top 10%

Papers in

Genetics 7
- Chronic Lymphocytic Leukemia Research 7
Pharmacology 5
- Pharmacogenetics and Drug Metabolism 5

Co-authors: Kent L. Kunze Kenneth E. Thummel W. Trager John P. McVicar Darlene Barr Danny D. Shen Christopher L. Marsh Vidmantas A. Raisys
Journals: Drug Metabolism and Disposition (5 papers)Journal of Pharmacology and Experimental Therapeutics (3 papers)Cancer Research (2 papers)Bioanalysis (2 papers)Blood (2 papers)
Partner nations: United States Poland Australia

In The Last Decade

Terry Podoll

21 papers receiving 863 citations

Peers

Countries citing papers authored by Terry Podoll

Since Specialization

Citations

This map shows the geographic impact of Terry Podoll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terry Podoll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terry Podoll more than expected).

Fields of papers citing papers by Terry Podoll

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terry Podoll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terry Podoll. The network helps show where Terry Podoll may publish in the future.

Co-authors

The 25 scholars most cited alongside Terry Podoll, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Terry Podoll Line = papers co-authored together Terry Podoll links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors Journal of Pharmacology and Experimental Therapeutics ·Terry Podoll, Paul G. Pearson, Allard Kaptein, Jerry Evarts, Gerjan de Bruin, Scott Van Zant, Anouk de Jong, Bart van Lith, Hao Sun, Stephen J. Byard, Adrian J. Fretland, Handayani Lubis Sri, Tjeerd Barf, J. Greg Slatter	2022	15
2	Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy Subjects Clinical Pharmacology in Drug Development ·Shekman Wong, Cecile M. Krejsa, Dana Lee, Maria Vittoria De Girolamo, Marine, Xiaohui Wang, Natalia Vilariño, Terry Podoll, Terry O’Reilly, J. Greg Slatter	2022	2
3	Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment The Journal of Clinical Pharmacology ·Yan Xu, Raquel Izumi, Helen Nguyen, Siwi Prihatiningsih, Alaa S. Abd-Elkader, R. Blum, J. Greg Slatter, Terry Podoll, Karthick Vishwanathan, Thomas Marbury, William B. Smith, Richard A. Preston, Shringi Sharma, Joseph A. Ware	2021	2
4	Effect of Food on MDM2 Inhibitor KRT-232 Pharmacokinetics and Macrophage Inhibitory Cytokine-1 (MIC-1) Response in Healthy Volunteers Blood ·Shekman Wong, Cecile M. Krejsa, Dana Lee, Maria Vittoria De Girolamo, Marine, Xiaohui Wang, Tiong Wee. Ng, Natalia Vilariño, Terry Podoll, Terry O’Reilly, J. Greg Slatter	2020	1
5	A Mechanistic Physiologically Based Pharmacokinetic (PBPK) Drug Interaction Model for the Mouse Double Minute 2 (MDM2) Inhibitor KRT-232 Blood ·Ian E. Templeton, Terry Podoll, Cecile M. Krejsa, J. Greg Slatter	2020	2
6	Oxidative Deamination of Emixustat by Human Vascular Adhesion Protein-1/Semicarbazide-Sensitive Amine Oxidase Drug Metabolism and Disposition ·Michael Reid, Yuliya Vladimirovna Belskaya, Terry Podoll	2019	6
7	Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach CPT Pharmacometrics & Systems Pharmacology ·Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph A. Ware, J. Greg Slatter, Nidal Al‐Huniti	2019	39
8	Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity Cancer Research ·Allard Kaptein, Terry Podoll, Gerjan de Bruin, Scott Van Zant, Anouk de Jong, Bart van Lith, Handayani Lubis Sri, Tjeerd Barf, Joseph A. Ware, J. Greg Slatter	2019	6
9	Abstract 13: Structure elucidation, metabolism, and drug interaction potential of ACP-5862, an active, major, circulating metabolite of acalabrutinib Cancer Research ·Terry Podoll, Paul G. Pearson, Jerry Evarts, Saulo Amaral Carminati, Hao Sun, Stephen J. Byard, Adrian J. Fretland, J. Greg Slatter	2019	9
10	Abstract 13: Structure elucidation, metabolism, and drug interaction potential of ACP-5862, an active, major, circulating metabolite of acalabrutinib Terry Podoll, Paul G. Pearson, Jerry Evarts, Saulo Amaral Carminati, Hao Sun, Stephen J. Byard, Adrian J. Fretland, J. Greg Slatter	2019	1
11	Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans Drug Metabolism and Disposition ·Terry Podoll, Paul G. Pearson, Jerry Evarts, Saulo Amaral Carminati, Елена Бибикова, Hao Sun, Mark Gohdes, ميساء عبد القادر, Mitesh Sanghvi, J. Greg Slatter	2018	50
12	Bioanalysis of Emixustat (Acu-4429) in Whole Blood Collected with Volumetric Absorptive Microsampling by LC–MS/MS Bioanalysis ·Zhixin Miao, Larissa Fortaleza Silva, 石岡卓也, Terry Podoll, Michael Reid	2015	31
13	Comparative Ocular Tissue Distribution Kinetics of the Visual Cycle Modulator (VCM) Emixustat-HCl in Rats, Beagle Dogs, and Cynomolgus Monkeys Terry Podoll, Suliman Al‐Fayoumi, Cárdenas Barria José Luis, John Chandler, Ryo Kubota	2013	1
14	Ocular Distribution of the Visual Cycle Modulator (VCM) 14C-ACU-4429 in Beagle Dogs Investigative Ophthalmology & Visual Science ·Terry Podoll, Suliman Al‐Fayoumi, Cárdenas Barria José Luis, Gang Sun, John Chandler, Ryo Kubota	2012	1
15	Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC Bioorganic & Medicinal Chemistry Letters ·Joseph S. Warmus, Cheryl L. Quinn, Clarke Taylor, Sean T. Murphy, Timothy A. Johnson, Chris Limberakis, Daniel F. Ortwine, Joel C. Bronstein, Pustyl'nik AIu, John D. Knafels, Sandra Lightle, Igor Mochalkin, Roger J. Brideau, Terry Podoll	2012	28
16	IN VITRO METABOLISM OF CLINDAMYCIN IN HUMAN LIVER AND INTESTINAL MICROSOMES Drug Metabolism and Disposition ·Michael A. Wynalda, J. Matthew Hutzler, Ileana Vega-Guzmán, Terry Podoll, Larry C. Wienkers	2003	71
17	Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metabolism and Disposition ·Rita Labroo, Kenneth E. Thummel, Kent L. Kunze, Terry Podoll, W. Trager, Evan D. Kharasch	1995	54
18	Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics ·Kenneth E. Thummel, Danny D. Shen, Terry Podoll, Kent L. Kunze, W. Trager, Rawda Ashraf, Vidmantas A. Raisys, Christopher L. Marsh, John P. McVicar, Darlene Barr	1994	310
19	Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and Experimental Therapeutics ·Kenneth E. Thummel, Danny D. Shen, Terry Podoll, Kent L. Kunze, W. Trager, Carlos E. Bacchi, Christopher L. Marsh, John P. McVicar, Darlene Barr, James D. Perkins	1994	194
20	Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metabolism and Disposition ·Kenneth E. Thummel, Evan D. Kharasch, Terry Podoll, Kent L. Kunze	1993	79

About Terry Podoll

Terry Podoll is a scholar working on Genetics, Pharmacology, Pathology and Forensic Medicine, Pharmaceutical Science and Biochemistry, having authored 21 papers that have together received 904 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Pharmacogenetics and Drug Metabolism (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Drug Transport and Resistance Mechanisms (2 papers), Biochemical and Molecular Research (2 papers), Chronic Myeloid Leukemia Treatments (2 papers) and Biochemical effects in animals (2 papers). The work is most often cited by research in Pharmacology (535 citations), Transplantation (39 citations), Oncology (335 citations), Anesthesiology and Pain Medicine (57 citations) and Pediatrics, Perinatology and Child Health (195 citations). Terry Podoll has collaborated with scholars based in United States, Poland and Australia. Frequent co-authors include Kent L. Kunze, Kenneth E. Thummel, W. Trager, John P. McVicar, Darlene Barr, Danny D. Shen, Christopher L. Marsh, Vidmantas A. Raisys, Evan D. Kharasch and James D. Perkins. Their work appears in journals such as Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, Cancer Research, Bioanalysis and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact